Digital Disruption: Innovation and Health Plan Design & Health Insurance

In commercial health insurance, innovations are taking place to re-imagine health plan design. Daniel Corliss, Chief Executive Manager and Founding Partner at BSP (Business Stimulus Partners), and DC Angel spoke with Digital Disruption’s Hilary Kennedy about the changes he’s seeing.

“A lot is going on, but some of the critical components that are teed up for us today are the transparency laws that have taken effect,” Corliss said. These changes make hospital reimbursements and their contracts with different insurance providers non-secretive. “And so, every hospital system in the United States is supposed to be posting their contracts and their cash prices for all of their chargemaster services.”

Corliss said the current changes help determine the healthcare innovators worthy of investment from the venture capital side.

“I love the VC space because I can identify health tech entrepreneurs and founders that are creating awesome business models, technology, and products and services for the health plans that I serve,” Corliss said. “If I see something that I really like, and I see a startup that they’re doing things sustainably, ethically, and responsibly, and I want to help promote their growth and their success, I can invest capital into that company and then also insert them into the healthcare ecosystems and channel partnerships, to get them to rapid, scalable growth for that technology.”

Sometimes, Corliss said, innovators get stuck because they have great technology but don’t know what to do with it or how to make the right connections to bring the technology into the marketplace in a scalable way. That’s where businesses like Health Wallet can help make sense of the technology and put it to use.

Recent Episodes

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…